Prima BioMed (IMMP) Competitors $1.73 +0.09 (+5.49%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.71 -0.02 (-1.16%) As of 09/15/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. CRON, CRMD, TSHA, IMNM, AMLX, IOVA, PHAT, URGN, TRVI, and DNTHShould you be buying Prima BioMed stock or one of its competitors? The main competitors of Prima BioMed include Cronos Group (CRON), CorMedix (CRMD), Taysha Gene Therapies (TSHA), Immunome (IMNM), Amylyx Pharmaceuticals (AMLX), Iovance Biotherapeutics (IOVA), Phathom Pharmaceuticals (PHAT), Urogen Pharma (URGN), Trevi Therapeutics (TRVI), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Prima BioMed vs. Its Competitors Cronos Group CorMedix Taysha Gene Therapies Immunome Amylyx Pharmaceuticals Iovance Biotherapeutics Phathom Pharmaceuticals Urogen Pharma Trevi Therapeutics Dianthus Therapeutics Prima BioMed (NASDAQ:IMMP) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership. Is IMMP or CRON more profitable? Cronos Group has a net margin of 14.19% compared to Prima BioMed's net margin of 0.00%. Prima BioMed's return on equity of 0.00% beat Cronos Group's return on equity.Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Cronos Group 14.19%-3.78%-3.62% Do institutionals and insiders hold more shares of IMMP or CRON? 2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 3.1% of Prima BioMed shares are held by insiders. Comparatively, 7.3% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, IMMP or CRON? Cronos Group has higher revenue and earnings than Prima BioMed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$6.69M37.96-$39.78MN/AN/ACronos Group$130.28M7.49$41.08M$0.0551.00 Does the media refer more to IMMP or CRON? In the previous week, Cronos Group had 1 more articles in the media than Prima BioMed. MarketBeat recorded 3 mentions for Cronos Group and 2 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.86 beat Cronos Group's score of 0.81 indicating that Prima BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cronos Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend IMMP or CRON? Prima BioMed currently has a consensus target price of $7.00, suggesting a potential upside of 304.62%. Given Prima BioMed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Prima BioMed is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, IMMP or CRON? Prima BioMed has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. SummaryPrima BioMed beats Cronos Group on 8 of the 14 factors compared between the two stocks. Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricPrima BioMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$240.73M$3.15B$5.80B$10.18BDividend YieldN/A2.33%5.73%4.61%P/E RatioN/A21.2474.8626.39Price / Sales37.96467.22543.01125.40Price / CashN/A44.4425.8129.91Price / Book2.759.6413.256.28Net Income-$39.78M-$53.20M$3.29B$270.38M7 Day Performance8.12%0.07%0.07%1.89%1 Month PerformanceN/A4.27%4.60%6.01%1 Year Performance-25.11%9.62%72.96%25.26% Prima BioMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPPrima BioMed1.4601 of 5 stars$1.73+5.5%$7.00+304.6%-34.5%$240.73M$6.69M0.002,021CRONCronos Group2.4881 of 5 stars$2.48-0.8%N/A+17.0%$957.23M$117.61M49.60450CRMDCorMedix3.9112 of 5 stars$12.75+2.8%$17.33+35.9%+82.0%$925.65M$43.47M17.0030Analyst UpgradeTSHATaysha Gene Therapies2.4719 of 5 stars$3.24-3.6%$8.29+155.7%+31.9%$916.59M$8.33M-9.53180IMNMImmunome2.3212 of 5 stars$9.40-10.6%$22.89+143.5%-40.6%$915.71M$9.04M-3.0540Positive NewsAMLXAmylyx Pharmaceuticals2.1984 of 5 stars$10.44+2.4%$12.25+17.3%+352.3%$909.51M$87.37M-4.18200Positive NewsAnalyst ForecastGap UpIOVAIovance Biotherapeutics4.3343 of 5 stars$2.38-4.4%$11.90+400.0%-78.0%$901.02M$164.07M-1.93500Positive NewsPHATPhathom Pharmaceuticals2.3714 of 5 stars$12.43+0.7%$17.50+40.8%-37.3%$875.45M$55.25M-2.63110News CoveragePositive NewsURGNUrogen Pharma4.0707 of 5 stars$21.42+13.5%$32.00+49.4%+37.7%$873.47M$90.40M-6.45200Analyst UpgradeHigh Trading VolumeTRVITrevi Therapeutics2.8383 of 5 stars$7.60+8.4%$20.11+164.6%+139.2%$853.66MN/A-18.0920Positive NewsHigh Trading VolumeDNTHDianthus Therapeutics2.8784 of 5 stars$31.80+20.0%$54.00+69.8%+27.9%$852.99M$6.24M-9.7880High Trading Volume Related Companies and Tools Related Companies Cronos Group Alternatives CorMedix Alternatives Taysha Gene Therapies Alternatives Immunome Alternatives Amylyx Pharmaceuticals Alternatives Iovance Biotherapeutics Alternatives Phathom Pharmaceuticals Alternatives Urogen Pharma Alternatives Trevi Therapeutics Alternatives Dianthus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | SponsoredThe End of Elon Musk…?Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
